This company is no longer active
Angion Biomedica Management
Management criteria checks 3/4
Angion Biomedica's CEO is Jay Venkatesan, appointed in May 2018, they has a tenure of 5.08 years. Their total yearly compensation is $1.52M , comprised of 40% salary and 60% bonuses, including company stock and options. They directly owns 3.98% of the company’s shares, worth $1.20M. The average tenure of the management team and the board of directors is 3.5 years and 4.3 years respectively.
Key information
Jay Venkatesan
Chief executive officer
US$1.5m
Total compensation
| CEO salary percentage | 40.0% |
| CEO tenure | 5.1yrs |
| CEO ownership | 4.0% |
| Management average tenure | 3.5yrs |
| Board average tenure | 4.3yrs |
Recent management updates
Recent updates
Companies Like Angion Biomedica (NASDAQ:ANGN) Could Be Quite Risky
Apr 27
Angion Biomedica (NASDAQ:ANGN) Will Have To Spend Its Cash Wisely
Jan 05We Think Angion Biomedica (NASDAQ:ANGN) Needs To Drive Business Growth Carefully
Sep 11Angion Biomedica GAAP EPS of -$0.30, revenue of $0.7M misses by $0.08M
Aug 15Angion to discontinue phase 2 trial of ANG-3070 in patients with kidney disease
Jun 29We Think Angion Biomedica (NASDAQ:ANGN) Can Afford To Drive Business Growth
Mar 19Angion Biomedica: Selling At Cash Value
Feb 07Angion Biomedica Corp.'s (NASDAQ:ANGN) Intrinsic Value Is Potentially 49% Above Its Share Price
Oct 05We're Hopeful That Angion Biomedica (NASDAQ:ANGN) Will Use Its Cash Wisely
Aug 18CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Mar 31 2023 | n/a | n/a | -US$29m |
| Dec 31 2022 | US$2m | US$608k | -US$39m |
| Sep 30 2022 | n/a | n/a | -US$17m |
| Jun 30 2022 | n/a | n/a | -US$24m |
| Mar 31 2022 | n/a | n/a | -US$32m |
| Dec 31 2021 | US$3m | US$587k | -US$55m |
| Sep 30 2021 | n/a | n/a | -US$98m |
| Jun 30 2021 | n/a | n/a | -US$100m |
| Mar 31 2021 | n/a | n/a | -US$104m |
| Dec 31 2020 | US$1m | US$570k | -US$80m |
| Sep 30 2020 | n/a | n/a | -US$67m |
| Dec 31 2019 | US$2m | US$473k | -US$41m |
Compensation vs Market: Jay's total compensation ($USD1.52M) is above average for companies of similar size in the US market ($USD757.79K).
Compensation vs Earnings: Jay's compensation has been consistent with company performance over the past year.
CEO
Jay Venkatesan (51 yo)
5.1yrs
Tenure
US$1,518,849
Compensation
Dr. Jay R. Venkatesan, Ph D., M.D. MBA., serves as Chairman of Angion Biomedica Corp. since January 2022 and also serves as its President since January 2019 and has been its Chief Executive Officer & Direc...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 5.1yrs | US$1.52m | 3.98% $ 1.2m | |
| Executive VP | 3.4yrs | US$773.65k | 0.048% $ 14.6k | |
| Chief Financial Officer | 3yrs | US$1.38m | 0.013% $ 4.0k | |
| Vice President of Human Resources | 3.7yrs | no data | no data |
3.5yrs
Average Tenure
53yo
Average Age
Experienced Management: ANGN's management team is considered experienced (3.5 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 5.1yrs | US$1.52m | 3.98% $ 1.2m | |
| Lead Independent Non-Employee Director | 5.2yrs | US$93.78k | 3.25% $ 978.7k | |
| Independent Non-Employee Director | 3.4yrs | US$76.78k | 0.27% $ 80.3k | |
| Independent Non-Employee Director | 3.2yrs | US$81.28k | 0.062% $ 18.7k | |
| Chairperson of Scientific Advisory Board | no data | no data | no data | |
| Independent Non-Employee Director | 3.4yrs | US$78.78k | 0.031% $ 9.4k | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Chairman Emeritus | 25.2yrs | US$854.33k | 5.61% $ 1.7m | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data |
4.3yrs
Average Tenure
74yo
Average Age
Experienced Board: ANGN's board of directors are considered experienced (4.3 years average tenure).